QIAGEN's QuantiFERON-TB Test Wins Tender for Testing of Republic of Korea Armed Forces Recruits

HILDEN, Germany and SEOUL, January 26, 2017 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that QuantiFERON^®-TB Gold (QFT), the modern standard for accuracy in diagnosing latent tuberculosis (TB) infection, has been selected by the Republic of Korea Armed Forces for the screening of more than 340,000 recruits during 2017.

Korea has one of the highest active TB incidence rates among industrialized countries, with more than 32,000 new cases and 2,300 deaths per year. The government has adopted a strategy to eliminate the disease, including preventive screening of at-risk groups and treatment of individuals with latent tuberculosis infection (LTBI), in line with recommendations of the World Health Organization (WHO).

Furthermore, the Korea Centers for Disease Control and Prevention (CDC) in 2016 selected QuantiFERON-TB for nationwide contact screening of people at risk of infection through close contact with active TB patients.

"We are pleased to support the efforts in Korea to take a comprehensive, best-practice approach to TB control, and are collaborating with authorities, distributors and laboratories to implement a program for latent TB screening using QuantiFERON-TB as the modern test of choice," said Dr. Masae Kawamura, Senior Director, TB Medical and Scientific Affairs, at QIAGEN. QuantiFERON-TB is the standard test used by national laboratories in Korea and won this competitive tender for the Republic of Korea Armed Forces based on its proven workflow and cost effectiveness."

Click here for the full press release

https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID={AB5927E4-128B-4D19-BCDE-E0DA1E5395CE}&lang=en

Contacts:

QIAGEN
Investor Relations
John Gilardi
+49-2103-29-11711
e-mail: [email protected]

Public Relations
Dr. Thomas Theuringer    
+49-2103-29-11826
e-mail: [email protected]

SOURCE QIAGEN N.V.